Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Hydralazine

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Hydralazine is widely used as a peripheral vasodilator antihypertensive drug. During recent years, knowledge has accumulated on the pharmacokinetics of hydralazine in man. It is subjected to polymorphic N-acetylation, with phenotypically slow acetylators having higher steady state plasma concentrations and higher bioavailability of the drug in single dose studies, compared with subjects who are fast acetylators. However, the terminal elimination half-life of hydralazine is only slightly longer among slow acetylators, thus it does not seem very likely that polymorphic N-acetylation can represent the major metabolic pathway of the drug in man. Hydrallazine is subject to significant first-pass metabolism and there are indications that the N-acetylation process involved may be capacity-limited.

About 10% of a single oral dose can be recovered from the urine as the parent drug, but in spite of the apparent independence of renal function for its elimination thus suggested, hydrallazine is eliminated at a considerably slower rate in uraemic patients; possibly as a consequence of impaired hepatic metabolism or underestimation of the amount excreted unchanged in subjects with normal renal function. In spite of very high steady state plasma concentrations and prolonged clearance of hydrallazine in renal failure, no harmful effects have been reported. At least 2 active metabolites have been identified, but their clinical importance and kinetic properties have not been elucidated.

The duration of the hypotensive effect of hydrallazine exceeds that predicted from the rate of elimination of the parent compound from plasma. Since there is no clear-cut correlation between the plasma concentration of the drug and its effect upon blood pressure, there is at present no reason to routinely measure plasma levels of hydrallazine in treated hypertensive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ablad, B.: Site of action of hydralazine and dihydralazine in man. Acta Pharmacologica et Toxicologica 16: 113–128 (1959).

    Article  PubMed  CAS  Google Scholar 

  • Ablad, B.: A study on the mechanism of the hemodynamic effects of hypotensive drugs in man. Acta Pharmacologica et Toxicologica 20 (Suppl. 1): 1–53 (1963).

    CAS  Google Scholar 

  • Alarcon-Segovia, D.; Wakim, K.G.; Worthington, J.W. and Ward, L.E.: Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine 46: 1–33 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Bloedow, D.C. and Hayton, W.L.: Saturable first-pass metabolism of sulfisoxazole N1-acetyl in rats. Journal of Pharmaceutical Sciences 65: 334–338 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Cohen, A.S.; Reynolds, W.E.; Franklin, E.C.; Kulka, J.P.; Ropes, M.W.; Shulman, L.E. and Wallace, S.L.: Preliminary criteria for the classification of systemic lupus erythematosus. Bulletin on the rheumatic diseases 21: 643–648 (1971).

    Google Scholar 

  • Cooper, I.: Maintenance treatment of moderate hypertension with b.i.d. hydralazine. Current Therapeutic Research 20: 579–588 (1976).

    Google Scholar 

  • Drucker M.; Blondheim, S.H. and Wislicki, L.: Factors affecting acctylation in-vivo of para-aminobenzoic acid in human subjects. Clinical Sciences 27: 133–141 (1964).

    CAS  Google Scholar 

  • Druey, J. and Ringier, B.H.: Hydralazinderivate der Phthalazine-und Pyridazinreihe. Helvetica Chimica Acta 34: 195–210 (1951).

    Article  CAS  Google Scholar 

  • Dustan, H.P.; Taylor, R.D.; Corcoran, A.C. and Page, I.H.: Rheumatic and febrile syndrome during prolonged hydralazine treatment. Journal of the American Medical Association 154: 23–29 (1954).

    Article  PubMed  CAS  Google Scholar 

  • Edwards, S. and Marquardt, F.-H.: The metabolism of l-hydrazino-phthalazine: The correct structure of the pseudo-“N-acetyl-l-hydrazinophthalazine.” Hoppe-Zeylers Zeitschrift fur physiologische Chemie 350: 85–86 (1969).

    Article  CAS  Google Scholar 

  • Evans, D.A.P. and White, T.: Human acetylation polymorphism. Journal of Laboratory and Clinical Medicine 63: 394–403 (1964).

    PubMed  CAS  Google Scholar 

  • Freis, E.D.; Rose, J.C. and Higgins, T.F.: The hemodynamic effects of hypotensive drugs in man. IV. l-hydrazinophthalazine. Circulation 8: 199–204 (1953).

    Article  PubMed  CAS  Google Scholar 

  • Gottlieb, T.B.; Katz, F.H. and Chidsey, C.A.: Combined therapy with vasodilators and beta-adrenergic blockade in hypertension. A comparative study on minoxidil and hydralazine. Circulation 45: 571–582 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Graffner, G.: Elimination rate of N-acetyl-procainamide after a single intravenous dose of procainamide hydrochloride in man. Journal of Pharmacokinetics and Biopharmaceutics 3: 69–76 (1975).

    PubMed  CAS  Google Scholar 

  • Gross, F.; Druey, J. and Meier, R.: Eine neue Gruppe Blutdrucksenkender Substanzen von besonderer Wirkungscharakter. Experientia 6: 19–21 (1950).

    Article  PubMed  CAS  Google Scholar 

  • Hahn, B.H.; Sharp, G.C.; Irvin, W.S.; Kantor, O.S.; Gardner, C.A.; Bagby, M.K.; Perry, H.M. and Osterland, C.K.: Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus. Annals of Internal Medicine 76: 365–374 (1972).

    PubMed  CAS  Google Scholar 

  • Haegle, K.D.; Skrdlant, H.B.; Robie, N.W.; Lalka, D. and McNay, J.L.: Determination of hydralazine and metabolites by gas-chromatography-mass spectrometry. Journal of Chromatography 126: 517–534 (1976).

    Article  Google Scholar 

  • Hansson, A. and Melander, A.: Person Communication (1977).

  • Hearse, D.J. and Weber, W.W.: Multiple N-acetyltransferases and drug metabolism. Biochemical Journal 132: 519–526 (1973).

    PubMed  CAS  Google Scholar 

  • Israili, Z.H.; Dayton, P.C.; Segal, J.L.; Leifer, C.E.; O’Malley, K.; Gilbert, J.C. and McNay, J.L.: Further studies with hydralazine-14C (H-14C) and metabolites. Abstract from paper presented at the VIth International Congress on Pharmacology. Helsinki. July 20–25th (1975).

    Google Scholar 

  • Jack, D.B.; Brechbuhler, S.; Degen, P.H.; Zbinden, P. and Riess, W.: The determination of hydralazine in plasma by gas-liquid-chromatography. Journal of Chromatography 115: 87–92 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Jenne, J.W.: Studies on the human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method. American Review of Respiratory Diseases 81: 1–7 (1960).

    CAS  Google Scholar 

  • Jounela, A.J.; Pasanen, M. and Mattila, M.J.: Acetylator phenotype and antihypertensive response to hydralazine. Acta Medica Scandinavica 197: 303–306 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Kirpekar, S.M. and Lewis, J.J.: Pharmacological properties of hydralazine, dihydralazine and related compounds. Journal of Pharmacy and Pharmacology 9: 877–888 (1957).

    Article  PubMed  CAS  Google Scholar 

  • Larsson, R.; Karlsson, E. and Molin, L.: Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Medica Scandinavica 201: 223–226 (1977).

    Article  PubMed  CAS  Google Scholar 

  • LeSher, D.A.; Harris, L. and Hawkinson, B.A.: Comparison of b.i.d. vs. q.i.d. hydralazine dosage regimens in hypertensive patients on multiple drug therapy (Abstract). Clinical Pharmacology and Therapeutics 19: 110–111 (1976).

    Google Scholar 

  • Lesser, J.M.; Israili, Z.H.; Davis, D.C. and Dayton, P.G.: Metabolism and disposition of hydralazine-14C in man and dog. Drug Metabolism and Disposition 2: 351–360 (1974).

    PubMed  CAS  Google Scholar 

  • McLean, A.J.; Barron, K.; Haegle, K.D.; Carrier, O. and McNay, J.L.: Comparison of the pharmacodynamic effects of hydralazine, hydralazine acetonide, and triazolophthalazine (Abstract. Clin. Pharmacol. Ther. 21: 110 (1977).

    Google Scholar 

  • Moore-Jones, D and Perry, H.M.: Radioautographic localization of hydralazine-l-C14 in arterial walls. Proceedings of the Society for Experimental Biology and Medicine 122: 576–579 (1966).

    PubMed  CAS  Google Scholar 

  • Morrow, J.D.; Schroeder, H.A. and Perry, H.M.: Studies on the control of hypertension by Hyphex. II. Toxic reactions and side effects: Circulation 8: 829–839 (1953).

    PubMed  CAS  Google Scholar 

  • Moyer, J.H.: Hydralazine (Apresoline) hydrochloride. Archives of Internal Medicine 91: 419–439 (1953).

    Article  PubMed  CAS  Google Scholar 

  • Moyer, J.H.; Handley, C.A. and Huggins, R.A.: Further cardiovascular and renal studies following the administration of hydralazine and the effect of ganglionic blockade with hexamethonium on these responses. Journal of Pharmacology and Experimental Therapeutics 109: 175–182 (1953).

    PubMed  CAS  Google Scholar 

  • O’Malley, K.; Segal, J.L.; Israili, Z.H.; Boles, M.; McNay, J.L. and Dayton, P.G.: Duration of hydralazine action in hypertension. Clinical Pharmacology and Therapeutics 18: 581–586 (1975).

    PubMed  Google Scholar 

  • Pape, J.: The effect of alprenolol in combination with hydralazine in essential hypertension. Acta Medica Scandinavica 554 (Suppl.): 55–60 (1974).

    PubMed  CAS  Google Scholar 

  • Pentikainen, P.; Wan, S.H. and Azarnoff, D.L.: Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of Parasal and Pascorbic. American Review of Respiratory Diseases 108: 1340–1347 (1973).

    CAS  Google Scholar 

  • Perry, H.M.: Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. The American Journal of Medicine 54: 56–72 (1973).

    Article  Google Scholar 

  • Perry, H.M.; Schroeder, H.A. and Morrow, J.D.: Studies on the control of hypertension by Hyphex. IV. Levels of agents in urine and blood. American Journal of the Medical Sciences 228: 405–415 (1954).

    PubMed  CAS  Google Scholar 

  • Persson, I.: Combination therapy of essential hypertension with pindolol (Visken) and hydralazine. European Journal of Clinical Pharmacology 9: 91–93 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Reidenberg, M.M.: Drayer, D.; DeMarco, A.L. and Bello, C.T.: Hydralazine elimination in man. Clinical Pharmacology and Therapeutics 14: 970–977 (1973).

    PubMed  CAS  Google Scholar 

  • Reidenberg, M.M.; Kostenbauder, H.A. and Adams, W.: The rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients. Metabolism 18: 209–213 (1969).

    Article  PubMed  CAS  Google Scholar 

  • Reidenberg, M.M. and Martin, J.H.: The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metabolism and Disposition 2: 71–73 (1974).

    PubMed  CAS  Google Scholar 

  • Reidenberg, M.M.; Shear, L. and Cohen, R.V.: Elimination of isoniazid in patients with impaired renal function. American Review of Respiratory Diseases 108: 1426–1428 (1973).

    CAS  Google Scholar 

  • Reubi, F.C.: Renal hyperemia induced in man by a new phthalazine derivative. Proceedings of the Society for Experimental Biology and Medicine 73: 102–103 (1950).

    PubMed  CAS  Google Scholar 

  • Sannerstedt, R.; Stenberg, J.; Vedin, A.; Wilhelmsson, C. and Werkø, L.: Chronic beta-adrenergic blockade in arterial hypertension. American Journal of Cardiology 29: 718–723 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Schulert, A.R.: Physiological disposition of hydralazine (l-hydrazinophthalazine) and a method for its determination in biological fluids. Archives Internationales de Pharmacodynamie et de Therapie 132: 1–15 (1961).

    PubMed  CAS  Google Scholar 

  • Stein, D.H. and Hecht, H.H.: Cardiovascular and renal responses to the combination of hexamethonium and l-hydrazinophthalazine (Apresoline) in hypertensive subjects. Journal of Clinical Investigation 34: 867–874 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Strandberg, I.; Boman, G.; Hassler, L. and Sjoqvist, F.: Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Medica Scandinavica 200: 367–371 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Stunkard, A.; Wertheimer, L. and Redisch, W.: Studies on hydralazine: Evidence for a peripheral site of action. Journal of Clinical Investigation 33: 1047–1053 (1954).

    Article  PubMed  CAS  Google Scholar 

  • Talseth, T.: Studies on hydralazine. I. Serum concentrations of hydralazine after a single dose and at steady-state. European Journal of Clinical Pharmacology 10: 183–187 (1976a).

    Article  CAS  Google Scholar 

  • Talseth, T.: Studies on hydralazine. II. Elimination rate and steady-state concentrations in patients with impaired renal function. European Journal of Clinical Pharmacology 10: 311–317 (1976b).

    Article  PubMed  CAS  Google Scholar 

  • Talseth, T.: Studies on hydralazine. III. Bioavailability of hydralazine in man. European Journal of Clinical Pharmacology 10: 395–401 (1976c).

    Article  PubMed  CAS  Google Scholar 

  • Talseth, T.: Kinetics of hydralazine elimination. Clinical Pharmacology and Therapeutics 21: 715–720 (1977).

    PubMed  CAS  Google Scholar 

  • Talseth, T.; Fauchald, P. and Pape, J.F.: Hydralazine slow-release: Observations on serum profile and clinical efficacy. Current Therapeutic Research 21: 157–168 (1977).

    PubMed  CAS  Google Scholar 

  • Talseth, T. and Landmark, K.H.: Polymorphic acetylation of sulphadimidine in normal and uremic man. European Journal of Clinical Pharmacology 11: 33–36 (1977).

    Article  PubMed  CAS  Google Scholar 

  • van Oudtshoorn, M.C.B. and Potgieter, F.S.: Determination of pharmacokinetic parameters for rapid and slow acetylators of sulphadimidine. Journal of Pharmacy and Pharmacology 24: 357–360 (1972).

    Article  PubMed  Google Scholar 

  • Velasco, M.; Gilbert, C.A.; Rutledge, C.O. and McNay, J.L.: Antihypertensive effect of a dopamine hydroxylase inhibitor, bupicomide: A comparison with hydralazine. Clinical Pharmacology and Therapeutics 18: 145–153 (1975).

    PubMed  CAS  Google Scholar 

  • Wagner, J. and Hedwall, P.R.: Pharmacokinetics and pharmacological action of vasodilators; in Milliez and Safar (Eds) Recent Advances in Hypertension p. 331–342 (Societe Alinea, Reims 1975).

    Google Scholar 

  • Zacest, R.; Gilmore, E. and Koch-Weser, J.: Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. New England Journal of Medicine 286: 617–622 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Zacest, R. and Koch-Weser, J.: Relation of hydralazine plasma concentrations to dosage and hypotensive action. Clinical Pharmacology and Therapeutics 13: 420–425 (1972).

    PubMed  CAS  Google Scholar 

  • Zacest, R. and Stanley, P.E.: The influence of acetylator phenotype on plasma hydralazine levels in man following oral and intravenous administration; in Milliez and Safar (Eds) Recent Advances in Hypertension p. 343–351 (Societe Alinea, Reims 1975).

    Google Scholar 

  • Zak, S.B.; Bartlett, M.F.; Wagner, W.E.; Gilleran, T.G. and Lukas, G.: Disposition of hydralazine in man and a specific method for its determination in biological fluids. Journal of Pharmaceutical Sciences 63: 225–229 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Zimmer, H.; Glaser, R. and Kokosa, J.: 3-hydroxymethyl-s-triazolo-3.4. a-phthalazine, a novel urinary hydralazine metabolite in man. Journal of Medical Chemistry 18: 1031–1033 (1975).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department 9, Ullevaal Hospital, Oslo I, Norway

    Tore Talseth

Authors
  1. Tore Talseth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talseth, T. Clinical Pharmacokinetics of Hydralazine. Clin Pharmacokinet 2, 317–329 (1977). https://doi.org/10.2165/00003088-197702050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197702050-00001

Keywords

Search

Navigation